Shares of Novartis climbed on Tuesday following the release of positive late stage trial results for remibrutinib, an oral medication designed to treat relapsing multiple sclerosis. The Swiss pharmaceutical giant saw its stock rise 4.5 percent during European trading sessions as investors reacted to data suggesting the drug could become a significant new revenue stream for the company. This boost brings the stock’s total gain for the year to roughly 18 percent.
The success comes from two Phase III studies known as REMODEL-1 and REMODEL-2, which involved about 2,000 patients in total. Remibrutinib outperformed teriflunomide, a competing treatment sold by Sanofi, by significantly reducing annualized relapse rates and limiting the appearance of brain lesions on MRI scans. Beyond these metrics, the drug also demonstrated a promising ability to slow the progression of physical disability in patients.
One of the most critical takeaways for analysts was the drug’s safety profile regarding liver health. While other medications in the same class of inhibitors have struggled with regulatory hurdles due to liver toxicity, Novartis reported no such signals among more than 4,500 participants across various trials. UBS analyst Matt Weston described the drug as potentially best in class, noting that combining strong efficacy with a clean safety record makes it highly competitive against current options on the market.
Although two deaths occurred during the trials, investigators determined they were unrelated to the medication itself. Despite this, experts say they will continue to scrutinize detailed safety data as Novartis moves toward seeking regulatory approval in major global markets. Full details from the studies are expected to be presented at an upcoming medical conference in Toronto.
For Novartis, remibrutinib represents a vital piece of its long term growth strategy as it seeks to replace income lost from older blockbuster drugs facing generic competition. With another multiple sclerosis treatment already showing strong commercial growth, leadership believes there is still a massive unmet need for effective oral therapies that balance power with patient safety. This victory marks a successful start to a series of high profile readouts expected from the company’s pipeline later this year.